Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Who was against Ottesson filling the last seat at PDS again?

So you're suggesting that it would more wise to "grant" all creditors with 1% of PDS, thus giving PTSC a controlling interest (since PTSC is a creditor)? So, in essence, you suggest introducing all creditors as new added partners in PDS? Wow indeed! And after their debt is satisfied, they remain partners in PDS?

And I don't understand the mechanics of creditors somehow acquiring that 1%. Half a % from PTSC and half from TPL? Why would PTSC want to, or need to, give up even one half a percentage interest? The entire 1% from TPL? How is that more advantageous than PTSC acquiring that 1% as opposed to a countless number of creditors?

Perhaps you could offer a more thorough explanation of your thoughts....

And perhaps you could explain (away) how filling that third seat at PDS would NOT BE problematic, unless somehow handled as I suggest - through action by the Creditors Committee. Are you under the impression that PTSC and TPL would or could agree on a selection?

TIA,

SGE

Share
New Message
Please login to post a reply